AlexanderMontoMD

PubMed

• Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol-associated cirrh...
  Jeremy W Luk, Nghiem B Ha, Amy M Shui, Hannah R Snyder, Steven L Batki
  Alcohol, Clinical & Experimental Research. 2024-12-04
• Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease.
  Derek D Satre, Dhweeja Dasarathy, Steven L Batki, Michael J Ostacher, Hannah R Snyder
  Alimentary Pharmacology & Therapeutics. 2024-11-11
• Hepatocellular carcinoma after direct-acting antivirals for hepatitis C is associated with KIR-HLA types predicting weak NK cell-mediated immunity.
  James C Ryan, Christina Haight, Erene C Niemi, Joshua D Grab, Jennifer L Dodge
  European Journal of Immunology. 2024-08-01

Abstracts/Posters

• Role of retroviral restriction factors in the interferon-anpha-mediated suppression of HIV-1 in vivo.
  Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Rauch A, Cavassini M, Battegay M, Hirschel B, Vernazza P, Bernasconi E, Ledergerb, Proceedings of the National Academy of Sciences

Lectures

• Gastroenterology Division Fellows’ Course. 
  San Francisco, CA
• Liver Telehealth Resource Guide. 
  Department of Veterans Affairs, Veterans Health Administration
• Diagnosis and Management of Acute Hepatitis C. U.C.S.F. 
  24th Annual “The Medical Management of HIV/AIDS,” San Francisco, CA
• The Great Debate: When to treat hepatitis C in our HIV coinfected patients. 
  U.C.S.F. 24th Annual “The Medical Management of HIV/AIDS,” San Francisco, CA
• Hepatology Program. 
  U.C.S.F. Gastroenterology Division Grand Rounds, San Francisco, CA
• Updated VA HCV Treatment Recommendations: Genotype 1. 
  HCRC Pharmacist Preceptorship Program: Optimizing the Management of Hepatitis C
• Case Discussion: Hepatitis C. 
  Digestive Disease Week, San Diego, CA
• Liver Transplantation in HIV-infected Patients. 
  AASLD Clinical Symposium
• Liver Disease in Patients with HIV Infection. 
  Digestive Disease Week, San Diego, CA
• Hepatology Program. U.C.S.F. 
  Gastroenterology Division Grand Rounds, San Francisco, CA
• Is non-response to hepatitis C therapy associated with accelerated progression of liver disease? 
  Yale University Division of Digestive Diseases Research Seminar, New Haven, CT
• Cirrhosis and Portal Hypertension. 
  U.C.S.F. Gastroenterology Division Fellows’ Course, San Francisco, CA
• Current Diagnosis and Treatment of Hepatitis. 
  22nd Annual Meeting of the American Academy of Addiction Psychiatry, Scottsdale, AZ
• Hot Topics in Liver Disease. 
  Department of Veterans Affairs, in conjunction with AASLD Annual Meeting, 2008; 2010
• HIV and the Liver. 
  62nd Annual Meeting of the AASLD, San Francisco, CA
• Hepatitis C Treatment in 2011: Update on Current Treatments and the Role of Mental Health. 
  San Francisco VA Mental Health Grand Rounds
• Telaprevir and Boceprevir for Genotype 1 Treatment-Naïve Patients. 
  VHA Conference on Transforming Hepatitis C Care in VA
• Part II: Hepatitis C Therapy and New Oral HCV Protease Inhibitors. 
  VA Pharmacy Benefits Management-Medical Advisory Panel-VISN Pharmacy Executives Monthly Pharmacy
• Natural History of Hepatitis C and Cirrhosis. 
  Department of Veterans Affairs End-Stage Liver Disease Training Program, Washington D.C
• Focus on the Liver and Biliary Tract. 
  VA Schedule for Rating Disabilities Forum, Veterans Benefits Administration, Scottsdale, AZ
• Evaluation of Abnormal LFT’s, 2008. 
  U.C.S.F. Gastroenterology Division Fellows’ Course, San Francisco, CA
• New Hepatitis C Therapies. 
  Department of Veterans Affairs
• Hot Topics in Liver Disease. 
  Boston, MA
• Management of Hepatitis B and C infections. 
  U.C.S.F. Infectious Diseases Division Fellows’ Course, San Francisco, CA
• Hepatitis C and Immune Responses: Implications for New Therapies. 
  U.C.S.F. Gastroenterology Division Grand Rounds, San Francisco, CA
• Join now to see all

Other

• Implementation of a multidisciplinary team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. 
  Chang TT, Sawhney R, Monto A, Davoren JB, Kirkland JG, Stewart L, Corvera CU, HPB
• The epidemiology and prevention of hepatocellular carcinoma. 
  Monto A, Wright TL, Seminars in Oncology
• Hepatitis C and steatosis. 
  Monto A, Seminars in Gastrointestinal Disease
• Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. 
  Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL, Hepatology
• Recent perspectives on hepatitis C and human immunodeficiency virus coinfection. 
  Monto A, Wright TL, Hepatitis Index & Reviews
• Implications for disease progression and treatment. 
  Monto A. Alcohol and Hepatitis C, Current Hepatitis Reports
• Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransferases. 
  Hui CK, Monto A, Belaye T, Lau E, Wright TL, Gut
• Risks of a range of alcohol intake on hepatitis C-related fibrosis. 
  Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, Wright TL, Hepatology
• Hepatic steatosis in HIV- hepatitis C coinfection: prevalence and significance compared to hepatitis C monoinfection. 
  Monto A, Dove LM, Bostrom A, Kakar S, Tien P, Wright TL, Hepatology
• Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. 
  Huang H, Shiffman ML, Cheung RC, Layden TJ, Friedman S, Obar OT, Yee L, Chokkalingam AP, Schrodi SJ, Chan J, Catanese JJ, Leong DU, Ross D, Hu X, Monto A, McAllister LB, Gastroenterology
• The association of human immunodeficiency virus infection with spontaneous hepatitis C virus resolution and level of viremia among injection drug users. 
  Seal KH, Monto A, Dove L, Shen H, Vittinghoff E, Tracy D, Miller E, Lau E, Wright TL
• Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment. 
  Rempel H, Sun B, Calosing C, Abadjian L, Monto A, Pulliam L, PLoS ONE
• A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. 
  Currie SL, Ryan JC, Tracy D, Wright TL, George S, McQuaid R, Kim M, Shen H, Monto A, Drug and Alcohol Dependence
• Multidisciplinary perspectives on management of hepatocellular carcinoma: a roundtable discussion. 
  Monto A, Kohlwes J, Raval GG, Mehta P, El-Serag HB, Taddei T, Federal Practitioner
• Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C. 
  Chapko MK, Yee HS, Monto A, Dominitz JA, Vaccine
• Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: Non-Markov multistate model analysis. 
  Bacchetti P, Boylan RD, Astemborski J, Shen H, Mehta S, Thomas D, Terrault N, Monto A, PLoS ONE
• Retreatment with consensus interferon/ribavirin for hepatitis C following nonresponse or relapse to pegylated interferon and ribavirin: results from a national VA clin... 
  Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A, Digestive Diseases and Sciences
• Managing hepatitis C infection in the VA health care system: a roundtable discussion. 
  Ross D, Beste L, Dieperink E, Downey K, Monto A, Smith, J, Federal Practitioner Supplement
• Is IL28B genotype associated with more than one aspect of viral clearance? 
  Monto A, Ryan JC, Hepatology
• Nonresponse to interferon- anpha based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. 
  Cozen ML, Ryan JC, Shen H, Lerrigo R, Yee RM, Sheen E, Wu R, Monto A, PLoS ONE
• Impaired lymphocyte reactivity as measured by immune function testing in untransplanted patients with cirrhosis. 
  Yee RM, Lehil MS, Rongey C, Shen H, Cozen ML, Shen H, Monto A, Ryan JC, Clinical and Vaccine Immunology
• Join now to see all